BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 8042236)

  • 1. Prostaglandin E in the treatment of recurrent hepatitis B infection after orthotopic liver transplantation.
    Flowers M; Sherker A; Sinclair SB; Greig PD; Cameron R; Phillips MJ; Blendis L; Chung SW; Levy GA
    Transplantation; 1994 Jul; 58(2):183-92. PubMed ID: 8042236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation.
    Ben-Ari Z; Mor E; Shapira Z; Tur-Kaspa R
    Liver Transpl; 2001 Feb; 7(2):113-7. PubMed ID: 11172394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.
    Castells L; Vargas V; Rodríguez F; Allende H; Buti M; Sánchez-Avila JF; Jardí R; Margarit C; Pumarola T; Esteban R; Guardia J
    Liver Transpl; 2002 Oct; 8(10):892-900. PubMed ID: 12360430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lamivudine prophylaxis of liver allograft HBV reinfection in HBV related cirrhotic patients after liver transplantation.
    Lu SC; Yan LN; Li B; Wen TF; Zhao JC; Cheng NS; Liu C; Liu J; Wang XB; Li XD; Qin S; Zhao LS; Lei BJ; Zhang XH
    Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):26-32. PubMed ID: 14969833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of wild-type and precore mutant HBV infection after liver transplantation.
    Torre F; Wong PY; Macartney M; Williams R; Naoumov NV
    J Med Virol; 1999 Sep; 59(1):5-13. PubMed ID: 10440801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrence of hepatitis B in liver transplants treated with antiviral therapy.
    Marzano A; Debernardi-Venon W; Smedile A; Brunetto MR; Torrani Cerenzia MR; Actis GC; Zamboni F; Ghisetti V; Piantino P; David E; Salizzoni M; Rizzetto M
    Ital J Gastroenterol Hepatol; 1998 Feb; 30(1):77-81. PubMed ID: 9615271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation.
    Saab S; Yeganeh M; Nguyen K; Durazo F; Han S; Yersiz H; Farmer DG; Goldstein LI; Tong MJ; Busuttil RW
    Liver Transpl; 2009 Nov; 15(11):1525-34. PubMed ID: 19877207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained and focused hepatitis B virus nucleocapsid-specific T-cell immunity in liver transplant recipients compared to individuals with chronic and self-limited hepatitis B virus infection.
    Bihl F; Loggi E; Chisholm JV; Biselli M; Morelli MC; Cursaro C; Terrault NA; Bernardi M; Bertoletti A; Andreone P; Brander C
    Liver Transpl; 2008 Apr; 14(4):478-85. PubMed ID: 18324666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after liver transplantation.
    Ben-Ari Z; Zemel R; Kazetsker A; Fraser G; Tur-Kaspa R
    Am J Gastroenterol; 1999 Mar; 94(3):663-7. PubMed ID: 10086648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should liver transplantation be performed for patients with hepatitis B?
    Eason JD; Freeman RB; Rohrer RJ; Lewis WD; Jenkins R; Dienstag J; Cosimi AB
    Transplantation; 1994 Jun; 57(11):1588-93. PubMed ID: 8009592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation.
    Hussain M; Soldevila-Pico C; Emre S; Luketic V; Lok AS;
    Liver Transpl; 2007 Aug; 13(8):1137-44. PubMed ID: 17663390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series.
    Huang YW; Liu CJ; Lai MY; Lee PH; Tsai MK; Wang SS; Lai MK; Kao JH
    Clin Ther; 2006 Sep; 28(9):1327-34. PubMed ID: 17062306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation.
    Segovia R; Sánchez-Fueyo A; Rimola A; Grande L; Bruguera M; Costa J; Soguero C; Uriz J
    Liver Transpl; 2001 Feb; 7(2):106-12. PubMed ID: 11172393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection.
    Su WJ; Ho MC; Ni YH; Chen HL; Hu RH; Wu YM; Chang MH; Lee PH
    J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):203-8. PubMed ID: 19179883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotype prevalence, viral load and outcome of hepatitis B virus precore mutant infection in stable patients and in patients after liver transplantation.
    Ben-Ari Z; Ashur Y; Daudi N; Shmilovitz-Wiess H; Brown M; Sulkes J; Klein A; Mor E; Tur-Kaspa R; Shouval D
    Clin Transplant; 2004 Aug; 18(4):415-22. PubMed ID: 15233819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation.
    Fontana RJ; Hann HW; Wright T; Everson G; Baker A; Schiff ER; Riely C; Anschuetz G; Riker-Hopkins M; Brown N;
    Liver Transpl; 2001 Jun; 7(6):504-10. PubMed ID: 11443577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients.
    Chan TM; Fang GX; Tang CS; Cheng IK; Lai KN; Ho SK
    Hepatology; 2002 Nov; 36(5):1246-52. PubMed ID: 12395336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.
    Yu AS; Vierling JM; Colquhoun SD; Arnaout WS; Chan CK; Khanafshar E; Geller SA; Nichols WS; Fong TL
    Liver Transpl; 2001 Jun; 7(6):513-7. PubMed ID: 11443579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver transplantation in European patients with the hepatitis B surface antigen.
    Samuel D; Muller R; Alexander G; Fassati L; Ducot B; Benhamou JP; Bismuth H
    N Engl J Med; 1993 Dec; 329(25):1842-7. PubMed ID: 8247035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients].
    Yang Y; Yang Y; Zhang J; Yi HM; Lu MQ; Cai CJ; Li X; Jiang N; Xu C; Li H; Wang GS; Yi SH; Zhang JF; Jiang H; Yang Q; Chen GH
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1810-2. PubMed ID: 18971179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.